Vanguard Global Advisers’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.3M Buy
38,447
+1,247
+3% +$49.1K ﹤0.01% 1543
2026
Q2
$1.43M Buy
37,200
+3,577
+11% +$109K ﹤0.01% 1508
2026
Q1
$835K Buy
+33,623
New +$870K ﹤0.01% 1755

Other funds holding IMVT

Vanguard Global Advisers's IMVT Position: Q3 2026 in Review

Vanguard Global Advisers increased its Immunovant (IMVT) stake by 3.4% in Q3 2026, buying an estimated $49.1K and bringing the position to 38,447 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1543.

Vanguard Global Advisers first reported a position in IMVT in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.43M in Q2 2026. 232 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • Vanguard Global Advisers held 38,447 shares of Immunovant worth $1.3M as of Q3 2026.
  • Vanguard Global Advisers bought 1,247 Immunovant shares in Q3 2026, an estimated $49.1K.
  • Immunovant made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1543 holding.
  • Vanguard Global Advisers first reported a position in Immunovant in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Immunovant position peaked at $1.43M in Q2 2026.
  • 232 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.